Trinity Biotech plc Net Income
| TRIB Stock | USD 0.87 0.07 8.75% |
As of the 10th of February, Trinity Biotech has the Risk Adjusted Performance of 0.0348, semi deviation of 5.57, and Coefficient Of Variation of 3108.51. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Trinity Biotech plc, as well as the relationship between them.
Trinity Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Trinity Biotech's valuation are provided below:Trinity Biotech plc does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Trinity Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Trinity Biotech plc's market price often diverges from its book value, the accounting figure shown on Trinity's balance sheet. Smart investors calculate Trinity Biotech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Trinity Biotech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Trinity Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Trinity Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Trinity Biotech.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Trinity Biotech on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Trinity Biotech plc or generate 0.0% return on investment in Trinity Biotech over 90 days. Trinity Biotech is related to or competes with Advanced Biomed, BioNexus Gene, Beyond Air, Marker Therapeutics, SINTX Technologies, Evogene, and Sensei Biotherapeutics. Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laborator... More
Trinity Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Trinity Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Trinity Biotech plc upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.98 | |||
| Information Ratio | 0.0214 | |||
| Maximum Drawdown | 64.13 | |||
| Value At Risk | (8.97) | |||
| Potential Upside | 12.86 |
Trinity Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Trinity Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Trinity Biotech's standard deviation. In reality, there are many statistical measures that can use Trinity Biotech historical prices to predict the future Trinity Biotech's volatility.| Risk Adjusted Performance | 0.0348 | |||
| Jensen Alpha | 0.1503 | |||
| Total Risk Alpha | (0.62) | |||
| Sortino Ratio | 0.0262 | |||
| Treynor Ratio | 0.1904 |
Trinity Biotech February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0348 | |||
| Market Risk Adjusted Performance | 0.2004 | |||
| Mean Deviation | 4.99 | |||
| Semi Deviation | 5.57 | |||
| Downside Deviation | 6.98 | |||
| Coefficient Of Variation | 3108.51 | |||
| Standard Deviation | 8.57 | |||
| Variance | 73.39 | |||
| Information Ratio | 0.0214 | |||
| Jensen Alpha | 0.1503 | |||
| Total Risk Alpha | (0.62) | |||
| Sortino Ratio | 0.0262 | |||
| Treynor Ratio | 0.1904 | |||
| Maximum Drawdown | 64.13 | |||
| Value At Risk | (8.97) | |||
| Potential Upside | 12.86 | |||
| Downside Variance | 48.76 | |||
| Semi Variance | 31.06 | |||
| Expected Short fall | (8.73) | |||
| Skewness | 2.08 | |||
| Kurtosis | 10.85 |
Trinity Biotech plc Backtested Returns
Trinity Biotech appears to be abnormally volatile, given 3 months investment horizon. Trinity Biotech plc owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0322, which indicates the firm had a 0.0322 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Trinity Biotech plc, which you can use to evaluate the volatility of the company. Please review Trinity Biotech's Semi Deviation of 5.57, risk adjusted performance of 0.0348, and Coefficient Of Variation of 3108.51 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Trinity Biotech holds a performance score of 2. The entity has a beta of 1.4, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Trinity Biotech will likely underperform. Please check Trinity Biotech's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Trinity Biotech's existing price patterns will revert.
Auto-correlation | 0.45 |
Average predictability
Trinity Biotech plc has average predictability. Overlapping area represents the amount of predictability between Trinity Biotech time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Trinity Biotech plc price movement. The serial correlation of 0.45 indicates that just about 45.0% of current Trinity Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.45 | |
| Spearman Rank Test | 0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Trinity Biotech plc reported net income of (31.79 Million). This is 109.31% lower than that of the Health Care Equipment & Supplies sector and 118.36% lower than that of the Health Care industry. The net income for all United States stocks is 105.57% higher than that of the company.
Trinity Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Trinity Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Trinity Biotech could also be used in its relative valuation, which is a method of valuing Trinity Biotech by comparing valuation metrics of similar companies.Trinity Biotech is currently under evaluation in net income category among its peers.
Trinity Fundamentals
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.52) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 125.98 M | ||||
| Shares Outstanding | 18.63 M | ||||
| Shares Owned By Insiders | 12.01 % | ||||
| Shares Owned By Institutions | 65.77 % | ||||
| Number Of Shares Shorted | 351.46 K | ||||
| Price To Earning | 31.00 X | ||||
| Price To Book | 5.11 X | ||||
| Price To Sales | 0.31 X | ||||
| Revenue | 61.55 M | ||||
| Gross Profit | 21.44 M | ||||
| EBITDA | (16.91 M) | ||||
| Net Income | (31.79 M) | ||||
| Cash And Equivalents | 10.01 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 100.76 M | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | (1.96) X | ||||
| Cash Flow From Operations | (4.19 M) | ||||
| Short Ratio | 0.61 X | ||||
| Earnings Per Share | (1.80) X | ||||
| Price To Earnings To Growth | 1.30 X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 401 | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 15.89 M | ||||
| Total Asset | 103.29 M | ||||
| Retained Earnings | (79.12 M) | ||||
| Working Capital | 9.03 M | ||||
| Current Asset | 151 M | ||||
| Current Liabilities | 21 M | ||||
| Net Asset | 103.29 M |
About Trinity Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Trinity Biotech plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Trinity Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Trinity Biotech plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Trinity Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Trinity Biotech plc's market price often diverges from its book value, the accounting figure shown on Trinity's balance sheet. Smart investors calculate Trinity Biotech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Trinity Biotech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.